TMAO: Which Tests to Order Alongside for a Complete Cardiovascular Risk Picture

What TMAO Is and Why It Matters for Cardiovascular Risk

Trimethylamine N-oxide is a small organic compound produced when intestinal bacteria convert dietary choline, phosphatidylcholine, L-carnitine, and betaine into trimethylamine (TMA), which the liver then oxidizes to TMAO via flavin monooxygenase 3 (FMO3). The landmark 2011 study by Wang et al. in Nature (N=1,876) first identified plasma TMAO as an independent predictor of cardiovascular disease in humans [1]. A subsequent 2013 prospective cohort published in the New England Journal of Medicine (N=4,007) found that patients in the highest TMAO quartile had a 2.5-fold increased risk of MACE over three years, after adjusting for traditional risk factors [2].

But TMAO does not act in isolation. It accelerates atherosclerosis through multiple pathways: promoting macrophage foam cell formation, enhancing platelet hyperreactivity, and impairing reverse cholesterol transport [3]. Because these mechanisms intersect with inflammation, lipid metabolism, and renal clearance, a single TMAO value without companion biomarkers is difficult to act on clinically.

Dr. Stanley Hazen, Chair of Cellular and Molecular Medicine at the Cleveland Clinic Lerner Research Institute, has stated: "TMAO provides a window into a previously hidden pathway of cardiovascular risk, but interpreting it requires the context of a patient's inflammatory and metabolic profile" [2].

The Core Paired Panel: hs-CRP, Advanced Lipids, and Renal Function

Three tests form the minimum context for interpreting a TMAO result. Skip any one of them and you risk misclassifying risk.

High-sensitivity C-reactive protein (hs-CRP) quantifies systemic vascular inflammation. The JUPITER trial (N=17,802) demonstrated that statin therapy reduced cardiovascular events in patients with elevated hs-CRP even when LDL cholesterol was not elevated [4]. When TMAO and hs-CRP are both above their respective thresholds (6.2 μmol/L and 2.0 mg/L), the combination suggests active inflammatory atherosclerosis driven in part by the gut-vascular axis. A 2017 analysis in the Journal of the American Heart Association found that dual elevation of TMAO and hs-CRP predicted MACE with greater accuracy than either marker alone (HR 3.2 to 95% CI 2.1-4.8) [5].

Advanced lipid testing goes beyond standard total cholesterol, LDL-C, and HDL-C. Apolipoprotein B (apoB) or LDL particle number (LDL-P) captures atherogenic particle burden that LDL-C can miss, particularly in patients with metabolic syndrome or diabetes. The 2019 ESC/EAS guidelines recommend apoB as an alternative primary target for lipid-lowering therapy [6]. Pairing apoB with TMAO helps distinguish whether a patient's elevated gut-derived risk sits on top of a high particle burden or exists independently.

eGFR and serum creatinine are non-negotiable paired tests. TMAO is cleared almost entirely by the kidneys. Patients with chronic kidney disease (CKD) stage 3 or higher routinely show plasma TMAO concentrations two to five times higher than age-matched controls with normal renal function [7]. Without knowing eGFR, a clinician cannot determine whether an elevated TMAO reflects excessive gut production, impaired renal clearance, or both.

Lp(a): The Genetic Risk Layer TMAO Cannot Capture

Lipoprotein(a) operates on a completely different axis from TMAO. Where TMAO reflects diet-microbiome interaction, Lp(a) is 90% genetically determined and unresponsive to lifestyle modification [8]. The 2022 European Atherosclerosis Society consensus statement recommends measuring Lp(a) at least once in every adult's lifetime to identify inherited cardiovascular risk [8].

Why pair it with TMAO? A patient can have a pristine TMAO level and still carry a severely elevated Lp(a) above 50 mg/dL (or 125 nmol/L), placing them at two to three times the population risk for myocardial infarction. Conversely, a patient with high TMAO and normal Lp(a) may respond well to dietary intervention alone. The two markers together separate modifiable from non-modifiable risk, which directly informs whether a clinician prioritizes diet and microbiome strategies or adds pharmacotherapy.

The combination also matters for emerging therapies. Pelacarsen, an antisense oligonucleotide targeting Lp(a), completed the phase III Lp(a)HORIZON trial. Clinicians who already track both TMAO and Lp(a) will be positioned to identify candidates for Lp(a)-lowering agents while simultaneously managing gut-mediated risk.

Metabolic Context: HbA1c and Fasting Insulin

TMAO levels correlate with insulin resistance in observational data. A 2020 cross-sectional study in Diabetes Care (N=1,243) found that subjects in the highest TMAO tertile had significantly higher HOMA-IR scores than those in the lowest tertile (3.8 vs. 2.1, P<0.001) [9]. The directionality remains debated. TMAO may worsen insulin signaling, or insulin-resistant states may alter gut microbiome composition in ways that increase TMA production.

Regardless of causality, ordering HbA1c alongside TMAO accomplishes two things. First, it identifies whether the patient has prediabetes or frank type 2 diabetes, conditions that independently double cardiovascular risk per the ADA 2024 Standards of Care [10]. Second, it helps contextualize dietary counseling. A patient with both elevated TMAO and an HbA1c of 6.1% needs a dietary plan that addresses both carnitine/choline intake and glycemic load, not one or the other.

Fasting insulin, while not universally standardized, adds granularity in patients with normal HbA1c but suspected early insulin resistance. This is especially relevant in patients under 45 with elevated TMAO and a family history of metabolic syndrome.

Myeloperoxidase and Lp-PLA2: Vascular Inflammation Specificity

These two biomarkers move beyond systemic inflammation (hs-CRP's domain) into arterial-wall-specific inflammation.

Myeloperoxidase (MPO) is released by activated neutrophils within atherosclerotic plaques. The same Cleveland Clinic group that pioneered TMAO research demonstrated that MPO predicts near-term risk of acute coronary syndrome, even in troponin-negative chest pain patients [11]. TMAO and MPO share mechanistic overlap: TMAO upregulates macrophage scavenger receptors, while MPO oxidizes LDL within the intima. Ordering both markers in a patient presenting with atypical chest pain or known coronary artery disease provides a two-axis view of plaque vulnerability.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme bound to LDL particles that generates pro-inflammatory mediators within the arterial wall. The ARIC study (N=12,762) found that elevated Lp-PLA2 activity predicted ischemic stroke independently of traditional risk factors [12]. The ACC/AHA 2019 guidelines on primary prevention of cardiovascular disease list Lp-PLA2 as a risk-enhancing factor that can inform statin initiation decisions [13].

When paired with TMAO, Lp-PLA2 helps differentiate metabolic cardiovascular risk from plaque-specific enzymatic activity. A patient with high TMAO but normal Lp-PLA2 may have early-stage gut-driven atherogenesis without established plaque inflammation. A patient with both elevated signals warrants more aggressive lipid-lowering therapy.

Homocysteine and Folate: The Methylation Connection

Homocysteine testing pairs with TMAO through shared biochemistry. Both metabolites sit downstream of dietary methyl-donor metabolism. Choline, the primary dietary precursor of TMA, is also a methyl donor that feeds into the methionine-homocysteine cycle [14]. Patients with inadequate folate or vitamin B12 may accumulate homocysteine while simultaneously altering choline flux toward TMA production.

A 2018 systematic review in the American Journal of Clinical Nutrition (26 studies, N=11,484) found that plasma homocysteine above 15 μmol/L was associated with a 20% increase in coronary heart disease risk per 5 μmol/L increment [14]. Ordering homocysteine alongside TMAO identifies patients who might benefit from B-vitamin supplementation, which can reduce homocysteine without directly affecting TMAO but may shift choline metabolism in favorable directions.

The clinical action here is straightforward. If both homocysteine and TMAO are elevated, assess folate, B12, and B6 status. Correct deficiencies. Recheck both markers at 8 to 12 weeks.

NT-proBNP: Heart Failure Screening in TMAO-Elevated Patients

TMAO has a documented association with heart failure severity and prognosis. Tang et al. (2014) reported in the Journal of the American College of Cardiology that elevated TMAO in heart failure patients (N=720) predicted five-year mortality with a hazard ratio of 1.75 after adjustment for BNP levels and renal function [15]. The relationship is partly confounded by CKD, which impairs both TMAO clearance and volume regulation.

NT-proBNP or BNP should be included in the paired panel for patients over 50, patients with dyspnea, or patients with known structural heart disease. The 2022 AHA/ACC/HFSA heart failure guidelines recommend natriuretic peptide testing for heart failure screening in at-risk populations [16]. An elevated TMAO combined with an NT-proBNP above 125 pg/mL (the age-adjusted threshold varies) signals that the gut-cardiac axis may be contributing to myocardial stress.

How to Interpret the Full Panel: A Practical Framework

No single biomarker drives a treatment decision. The paired-panel approach works because each marker addresses a distinct axis of cardiovascular risk.

Order the TMAO paired panel as a single blood draw, fasting for at least 8 hours to ensure valid lipid and glucose values. The complete panel includes: TMAO, hs-CRP, apoB or LDL-P, total lipid panel, eGFR with serum creatinine, Lp(a) (one-time if never measured), HbA1c, fasting insulin (optional), homocysteine, MPO, and NT-proBNP (if age over 50 or symptomatic).

Dr. W.H. Wilson Tang, Department of Cardiovascular Medicine at the Cleveland Clinic, has noted: "The clinical utility of TMAO increases substantially when placed alongside established biomarkers of inflammation, renal function, and myocardial stress. No biomarker should be interpreted in a vacuum" [15].

For follow-up timing, recheck TMAO and hs-CRP at 12 weeks after dietary or pharmacologic intervention. Lp(a) does not need repeat measurement unless a targeted therapy is started. HbA1c follows its standard 3-month interval. eGFR should be rechecked if baseline values fall below 60 mL/min/1.73 m².

Dietary and Lifestyle Factors That Influence TMAO Levels

Reducing TMAO through diet is possible, and understanding the dietary drivers helps clinicians counsel patients with elevated results. Red meat is the strongest dietary contributor. A randomized crossover trial published in the European Heart Journal (N=113) demonstrated that a diet high in red meat increased plasma TMAO levels threefold compared with white meat or non-meat protein diets over four weeks [17]. The effect was reversible: TMAO levels normalized within four weeks of red meat cessation.

Eggs, often questioned as a choline source, have a more nuanced effect. While eggs contain phosphatidylcholine, a 2019 study in The American Journal of Clinical Nutrition (N=38) found that consuming three eggs daily for four weeks did not significantly raise fasting TMAO compared to a choline-matched non-egg control, likely because egg phosphatidylcholine is absorbed in the small intestine before reaching colonic bacteria [18].

Saltwater fish, particularly cod and halibut, contain free TMAO directly and can spike plasma levels acutely. This is a pre-formed source, not a gut-microbiome-mediated one, and typically clears within 24 hours. Clinicians should instruct patients to avoid fish for 24 hours before a TMAO blood draw to prevent false elevation.

Mediterranean-pattern diets rich in fiber, polyphenols, and fermented foods shift gut microbiome composition toward bacterial species that produce less TMA. Resveratrol and 3,3-dimethyl-1-butanol (DMB) have shown TMA-lyase inhibition in animal models, but no human RCT has confirmed clinical benefit from these compounds at the time of this review [3].

Patients asking how to raise TMAO levels should know that low TMAO is not a clinical concern. There is no recognized deficiency state.